Cartesian Therapeutics(RNAC.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Cartesian Therapeutics
RNAC.US
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
1.880 T
RNAC.USMarket value -Rank by Market Cap -/-

Financial Score

16/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking253/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE273.45%A
    • Profit Margin-4397.71%E
    • Gross Margin-2731.19%E
  • Growth ScoreE
    • Revenue YoY-97.72%E
    • Net Profit YoY83.01%A
    • Total Assets YoY-18.15%E
    • Net Assets YoY-4866.49%E
  • Cash ScoreE
    • Cash Flow Margin-2.27%D
    • OCF YoY-97.72%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio109.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cartesian Therapeutics (NASDAQ:RNAC) Given New $42.00 Price Target at Needham & Company LLC

    Needham & Company LLC has raised its price target for Cartesian Therapeutics (NASDAQ:RNAC) from $40.00 to $42.00, maintaining a "buy" rating. This suggests a potential upside of 436.33% from the current price. Other analysts have mixed views, with BTIG Research increasing their target to $44.00, while Wall Street Zen downgraded to "sell." Cartesian's stock is currently trading at $7.83, down 3.6%, with a market cap of $203.64 million. The company reported a quarterly loss of $1.38 per share, missing estimates, and had revenue of $0.45 million.

    Market Beat·
    US
    RNAC
    -3.66%
    Market Beat·
    US
    RNAC
    -3.66%

    FDA Accepts IND Application for Cartesian Therapeutics' Descartes-08 in Myositis

    Cartesian Therapeutics Inc. announced that the FDA has accepted its IND application for a Phase 2 clinical trial of Descartes-08 in myositis. The trial will assess the safety and efficacy of Descartes-08 in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome, starting in the first half of 2026. This approval allows for a randomized, double-blind, placebo-controlled trial, with potential for a seamless transition to a pivotal study based on interim results.

    Reuters·
    US
    RNAC
    -3.66%
    Reuters·
    US
    RNAC
    -3.66%

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | RNAC Stock News

    Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has reported significant progress in its clinical trials for Descartes-08, a cell therapy targeting autoimmune diseases. The Phase 3 AURORA trial for myasthenia gravis is on track, with positive safety data supporting outpatient administration. The FDA has accepted the IND application for a Phase 2 trial in myositis, expected to start in 1H26. Additionally, a Phase 1/2 trial for juvenile dermatomyositis has been initiated. The company anticipates sufficient cash resources to support operations through mid-2027, focusing on advancing its pipeline and exploring next-generation therapies.

    StockTitan·
    US
    RNAC
    -3.66%
    StockTitan·
    US
    RNAC
    -3.66%

    Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares

    Recent insider activity at Cartesian Therapeutics (RNAC) on January 8, 2026, revealed significant stock sales by top executives, including President & CEO Carsten Brunn, who sold 23,766 shares for $161,846. CFO Blaine Davis and CMO Milos Miljkovic also sold shares, totaling notable disposals. Additionally, the company announced inducement stock option grants for new employees, totaling 7,350 shares. Despite positive corporate updates, Spark's AI Analyst rates RNAC as Neutral due to weak financial performance and bearish technicals, with a current market cap of $183.1M and a YTD price performance of 7.63%.

    Tip Ranks·
    US
    RNAC
    -3.66%
    Tip Ranks·
    US
    RNAC
    -3.66%

    Chief Medical Officer Milos Miljkovic Reports Disposal of Cartesian Therapeutics Inc. Common Shares

    Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics Inc., reported the disposal of common shares of the company. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Cartesian Therapeutics Inc. is responsible for the original content published via EDGAR on January 08, 2026.

    Reuters·
    US
    RNAC
    -3.66%
    Reuters·
    US
    RNAC
    -3.66%
    © 2026 Longbridge｜Disclaimer